Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.

Type

Journal article

Journal

The Journal of rheumatology

Publication Date

12/2005

Volume

32

Pages

2477 - 2480

Addresses

University of California at Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu

Keywords

OMERACT 7 Special Interest Group, Fingers, Humans, Gastrointestinal Diseases, Kidney Diseases, Scleroderma, Localized, Scleroderma, Systemic, Skin Ulcer, Glomerular Filtration Rate, Health Status, Research Design, Quality of Life, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Outcome Assessment (Health Care), Clinical Trials as Topic